<DOC>
	<DOCNO>NCT01318135</DOCNO>
	<brief_summary>To evaluate efficacy safety alogliptin administer add-on sulfonylurea ( glimepiride ) metformin , daily ( QD ) , twice daily ( BID ) three time daily ( TID ) .</brief_summary>
	<brief_title>Long-term Safety Study Alogliptin Used Combination With Sulfonylurea Metformin Participants With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Both insulin hyposecretion insulin-resistance consider involved development type 2 diabetes mellitus . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient type 2 diabetes mellitus . Alogliptin inhibitor dipeptidyl peptidase IV ( DPP-IV ) enzyme . DPP-IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion . It expect inhibition DPP-IV improve glycemic control patient type 2 diabetes . This phase 2/3 , multicenter , open-label study , participant complete core phase 2/3 sulfonylurea add-on study ( SYR-322/CCT-005 ; NCT01318083 ) core phase 2/3 metformin add-on study ( SYR-322/CCT-006 ; NCT01318109 ) evaluate safety efficacy alogliptin administer add-on sulfonylurea ( glimepiride ) metformin continuously 40 week ( 52 week start study treatment alogliptin core phase 2/3 sulfonylurea add-on study core phase 2/3 metformin add-on study ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Common criterion applied participant complete core phase 2/3 sulfonylurea addon study complete core phase 2/3 metformin addon study : 1 . Had complete core phase 2/3 sulfonylurea addon study core phase 2/3 metformin addon study . 2 . Was capable understand comply protocol requirement . 3 . Signed write informed consent form prior initiation study procedure . Common criterion apply participant complete core phase 2/3 sulfonylurea addon study complete core phase 2/3 metformin addon study : 1 . With clinical manifestation hepatic impairment ( eg , aspartate aminotransferase alanine aminotransferase value 2.5 time upper reference limit Week 8 core phase 2/3 sulfonylurea addon study core phase 2/3 metformin addon study ) . 2 . With clinical manifestation renal impairment ( eg , creatinine value 1.5 time upper reference limit Week 8 core phase 2/3 sulfonylurea addon study core phase 2/3 metformin addon study ) . 3 . With serious cardiac disease , cerebrovascular disorder , serious pancreatic hematological disease ( eg , subject require hospital admission ) . Criteria apply participant complete core phase 2/3 metformin addon study : 1 . With history symptom lactic acidosis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Diabetes Mellitus - Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>